Cat. No.: HY-19807

Indirubin-3'-monoxime

Name: Indirubin-3'-monoxime
Brand: MedChemExpress
SKU: HY-19807
Price: 60.00 USD
Availability: InStock
Rating: 5 (4 reviews)

(Synonyms: Indirubin-3'-oxime)

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Indirubin-3'-monoxime is a potent GSK-3β inhibitor, and weakly inhibits 5-Lipoxygenase, with IC₅₀s of 22 nM and 7.8-10 µM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC₅₀s of 100 and 180 nM.

For research use only. We do not sell to patients.

Purity: 99.80%
CAS No.: 160807-49-8
Formula: C₁₆H₁₁N₃O₂
Molecular Weight:277.28

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Indirubin-3'-monoxime Chemical Structure

CAS No.: 160807-49-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[3]

GSK-3β

22 nM (IC₅₀)

CDK5/p25

100 nM (IC₅₀)

CDK1/cyclin B

180 nM (IC₅₀)

5-LOX

7.8-10 μM (IC₅₀)

All GSK-3 Isoforms :

All CDK Isoforms :

All Lipoxygenase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	62 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human lung carcinoma A549 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human lung carcinoma A549 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
Cancer cell lines	IC₅₀	>100 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human colon carcinoma Co12 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human colon carcinoma Co12 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
HCT-116	IC₅₀	12 μM Compound: 16	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19783149]
Hep 3B2	IC₅₀	9 μM Compound: Indirubin-3'-oxime	Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
HL-60	IC₅₀	>100 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human myeloid leukemia HL-60 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human myeloid leukemia HL-60 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
HL-60	IC₅₀	15.7 μM Compound: 16	Antiproliferative activity against human HL60 cells after 5 days by MTT assay Antiproliferative activity against human HL60 cells after 5 days by MTT assay	[PMID: 19783149]
HT-1080	IC₅₀	4.8 μM Compound: Indirubin-3'-monoxime	Inhibitory activity on the proliferation of Human fibrosarcoma HT1080 cancer cells using MTT or sulforhodamine B assay Inhibitory activity on the proliferation of Human fibrosarcoma HT1080 cancer cells using MTT or sulforhodamine B assay	[PMID: 15993584]
IMR-90	IC₅₀	18.2 μM Compound: 16	Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay	[PMID: 19783149]
K562	IC₅₀	>30 μM Compound: 16	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 19783149]
KB	IC₅₀	19.2 μM Compound: Indirubin-3'-oxime	Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MCF7	IC₅₀	25.5 μM Compound: Indirubin-3'-oxime	Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MKN-45	IC₅₀	36.7 μM Compound: Indirubin-3'-oxime	Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MV4-11	IC₅₀	0.15 μM Compound: 10	Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay	[PMID: 20153646]
NCI-H460	IC₅₀	32.6 μM Compound: Indirubin-3'-oxime	Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
RS4-11	IC₅₀	3.56 μM Compound: 10	Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay	[PMID: 20153646]
SF-268	IC₅₀	37 μM Compound: Indirubin-3'-oxime	Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
SH-SY5Y	IC₅₀	>25 μM Compound: 7a	Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	>25 μM Compound: 7a	Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	12 μM Compound: 7a	Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay	[PMID: 16854069]
SH-SY5Y	IC₅₀	13 μM Compound: 7a	Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay	[PMID: 16854069]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL10-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL15-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL4-induced Stat6 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat1 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL6-induced Stat3 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated IL7-induced Stat5 phosphorylation in BALB/c mouse CD8+ T cells by Phospho-Flow cytometry	[PMID: 18157122]
T-cell	IC₅₀	<20 μM Compound: 13, 13M	Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry Inhibition of JAK-mediated interferon-gamma-induced Stat1 phosphorylation in BALB/c mouse CD4+ T cells by Phospho-Flow cytometry	[PMID: 18157122]

In Vitro

Indirubin-3'-monoxime inhibits GSK-3β by competing with ATP, with K_i of 0.85 μM, and K_m of 110 μM. Indirubin-3'-monoxime also inhibits tau phosphorylation by GSK-3β, with an IC₅₀ value of around 100 nM. Indirubin-3'-monoxime completely inhibits the phosphorylation of the AT100 epitope^[1]. Indirubin-3'-monoxime inhibits vascular smooth muscle cell (VSMC) proliferation with IC₅₀ of ～2 μM. Indirubin-3'-monoxime blunts migration of VSMC stimulated with the PDGF. Indirubin-3'-monoxime interferes with the migratory response in VSMC, and also suppresses the production of pro-migratory LT in monocytes. Moreover, Indirubin-3'-monoxime inhibits 5-lipoxygenase (5-LO) product synthesis in monocytes and neutrophils, with the same potency (IC₅₀=5.0±1.1 and 3.7±1.2 μM, respectively). Indirubin-3'-monoxime is an inhibitor of 5-LO, with IC₅₀ of 7.8-10 μM in cell-free assay^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indirubin-3'-monoxime (0.1, 0.2 and 0.4 mg/kg, i.p) dose dependently reverses the cognitive impairment and combats the elevated oxidative stress markers in HFD fed mice. Indirubin-3'-monoxime also dose dependently lowers the serum glucose, TGs, TC and insulin levels, and improves the β-cell functioning in HFD fed mice. Moreover, Indirubin-3'-monoxime treatment significantly decreases HOMA-IR levels compared to HFD group. Indirubin-3'-monoxime (0.4 mg/kg) significantly attenuates the increased EL in the HFD group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 160807-49-8
Appearance Solid
Molecular Weight 277.28
Formula C₁₆H₁₁N₃O₂
Color Brown to red
SMILES

O=C1NC2=C(C=CC=C2)/C1=C3NC4=C(C=CC=C4)C\3=N/O
Synonyms

Indirubin-3'-oxime
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Biomark Res

A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28. [Abstract]

2025 Apr 7;13(1):57. PMID: 40197552
EBioMedicine

CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. [Abstract]

2024 Feb:100:104961. PMID: 38199044
EBioMedicine

Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. [Abstract]

2022 Apr;78:103950. PMID: 35344764
Biomed Pharmacother

Oncosis-like cell death is induced by berberine through ERK1/2-mediated impairment of mitochondrial aerobic respiration in gliomas. [Abstract]

2018 Jun:102:699-710. PMID: 29604589

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (450.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6065 mL

18.0323 mL

36.0646 mL

5 mM

0.7213 mL

3.6065 mL

7.2129 mL

10 mM

0.3606 mL

1.8032 mL

3.6065 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

GSK-3β is expressed in and purified from insect Sf9 cells. It is assayed, following a 1/100 dilution in 1 mg/mL BSA, 10 mM DTT, with 5 μL of 40 μM GS-1 peptide as a substrate, in buffer A, in the presence of 15 μM[γ-³²P]ATP (3000 Ci/mmol; 1 mCi/mL) in a final volume of 30 μL. After 30-min incubation at 30°C, 25-μL aliquots of supernatant are spotted onto 2.5×3-cm pieces of Whatman P81 phosphocellulose paper, and, 20 s later, the filters are washed five times (for at least 5 min each time) in a solution of 10 mL of phosphoric acid/liter of water. The wet filters are counted in the presence of 1 mL of ACS scintillation fluid^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

Cytotoxicity of Indirubin-3'-monoxime in monocytes is analysed by MTT assay in a 96-well format using a multi-well scanning spectrophotometer. Neutrophils (5×10⁶ cells/mL) or monocytes (2×10⁶ cells/mL) are incubated for 30 min with Indirubin-3'-monoxime, and the viability of the cells is analysed by MTT assay. Compared with vehicle (0.3% DMSO), no significant acute cytotoxicity is observed (neutrophils: 103.9±4.4%; monocytes: 129.4±5.4%; n=3, each)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Male mice (5-6 weeks old) are randomLy assigned into five groups (n=10). Group 1: receive normal pellet diet (NPD); Group 2: receive a HFD; Group 3-5 receive HFD for 8 weeks followed by Indirubin-3'-monoxime treatment (0.1, 0.2 and 0.4 mg/kg i.p, respectively) once daily for 1 week. Indirubin-3'-monoxime is dissolved in (2.5% v/v) DMSO in saline. The mice in NPD and HFD groups receive an equivalent volume of vehicle (2.5% v/v DMSO in saline). Doses of Indirubin-3'-monoxime are selected. Mice are kept under standard husbandry conditions (22±1°C and 60% humidity) and maintained on a 12/12-h light/dark schedule with free access to food and water for 8 weeks. Body weight is recorded weekly throughout the experimental period^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60. [Content Brief]

[2]. Sharma S, et al. Neuroprotective role of Indirubin-3'-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):1009-15. [Content Brief]

[3]. Blazevic T, et al. Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32. [Content Brief]

[4]. Cao Z, et al. Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer [published online ahead of print, 2021 Oct 8]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01311. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6065 mL	18.0323 mL	36.0646 mL	90.1616 mL
	5 mM	0.7213 mL	3.6065 mL	7.2129 mL	18.0323 mL
	10 mM	0.3606 mL	1.8032 mL	3.6065 mL	9.0162 mL
	15 mM	0.2404 mL	1.2022 mL	2.4043 mL	6.0108 mL
	20 mM	0.1803 mL	0.9016 mL	1.8032 mL	4.5081 mL
	25 mM	0.1443 mL	0.7213 mL	1.4426 mL	3.6065 mL
	30 mM	0.1202 mL	0.6011 mL	1.2022 mL	3.0054 mL
	40 mM	0.0902 mL	0.4508 mL	0.9016 mL	2.2540 mL
	50 mM	0.0721 mL	0.3606 mL	0.7213 mL	1.8032 mL
	60 mM	0.0601 mL	0.3005 mL	0.6011 mL	1.5027 mL
	80 mM	0.0451 mL	0.2254 mL	0.4508 mL	1.1270 mL
	100 mM	0.0361 mL	0.1803 mL	0.3606 mL	0.9016 mL

Bioz

Keywords

Indirubin-3'-monoxime

4 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Indirubin-3'-monoxime

Indirubin

9-ING-41

Indirubin-3′-oxime

PEG300

SB 216763

Ferrostatin-1

Acyclovir

Laduviglusib

GCN2iB

Camptothecin

Olverembatinib

Laduviglusib (GMP)

Publications Citing Use of MedChemExpress (MCE) Indirubin-3'-monoxime

All GSK-3 Isoforms

All CDK Isoforms

All Lipoxygenase Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Indirubin-3'-monoxime

Indirubin

9-ING-41

Indirubin-3′-oxime

PEG300

SB 216763

Ferrostatin-1

Acyclovir

Laduviglusib

GCN2iB

Camptothecin

Olverembatinib

Laduviglusib (GMP)

Publications Citing Use of MedChemExpress (MCE) Indirubin-3'-monoxime

All GSK-3 Isoforms

All CDK Isoforms

All Lipoxygenase Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Indirubin-3'-monoxime Related Classifications

HY-19807 Related Classifications

Bioz